(Q42280821)

19 October 2017

title

Long-term response rates of successful hepatitis B vaccination in HIV-infected patients (English)

1 reference

19 October 2017

5

1 reference

19 October 2017

Theodora de Vries-Sluijs

3

object named as

Theodora E M S de Vries-Sluijs

1 reference

19 October 2017

6

Martin Schutten

1 reference

19 October 2017

Marchina E. van der Ende

8

object named as

Marchina E van der Ende

1 reference

19 October 2017

Vania Baptista Lopes

1

1 reference

19 October 2017

Robert J Hassing

2

1 reference

19 October 2017

Abdel El Barzouhi

4

1 reference

19 October 2017

Robert A de Man

7

1 reference

19 October 2017

language of work or name

English

0 references

publication date

28 December 2012

1 reference

19 October 2017

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

19 October 2017

volume

31

1 reference

19 October 2017

issue

7

1 reference

19 October 2017

page(s)

1040-1044

1 reference

Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

A Randomized Controlled Study of Accelerated Versus Standard Hepatitis B Vaccination in HIV-Positive Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.12.047

10.1016/J.VACCINE.2012.12.047

7 January 2021

Identifiers

DOI

1 reference

19 October 2017

1 reference